# Viking Therapeutics VK2735: A Dual GLP-1/GIP Agonist with Potential for Triple Action

Canonical source: https://retacompare.com/research/viking-therapeutics-vk2735-dual-glp-1-gip-agonist-heading-toward-triple

Pipeline Candidates · 2026-05-02


    Viking Therapeutics' VK2735 is a dual agonist targeting GLP-1 and GIP receptors, poised to advance toward a triple-agonist approach. This positions it within a competitive landscape of next-generation obesity and metabolic therapies following the emergence of Retatrutide.

 The big picture

The landscape for obesity and metabolic disease treatments is evolving rapidly, particularly following the introduction of multi-agonist therapies such as Retatrutide. VK2735, developed by Viking Therapeutics, represents a significant addition to this pipeline. As a dual GLP-1/GIP agonist, VK2735 aims to leverage the complementary effects of these incretin pathways to enhance weight loss and metabolic control. The anticipated shift toward even higher-order agonists invites scrutiny regarding their efficacy, safety, and overall therapeutic potential in a market that is becoming increasingly crowded with innovative solutions.

 How it works

VK2735 functions by activating both GLP-1 (glucagon-like peptide-1) and GIP (gastric inhibitory polypeptide) receptors. GLP-1 is known for its role in enhancing insulin secretion, suppressing glucagon release, and promoting satiety, while GIP is involved in insulinotropic effects and fat metabolism. The design rationale for VK2735 centers around the hypothesis that dual receptor activation can provide synergistic benefits, potentially leading to improved weight management and metabolic outcomes. This dual action is believed to enhance glucose homeostasis and may offer a more robust therapeutic profile compared to single agonists.

 Key points at a glance

VK2735 is a dual agonist targeting GLP-1 and GIP receptors.

It is being developed by Viking Therapeutics for obesity and metabolic disorders.

The mechanism involves synergistic effects on insulin secretion and appetite regulation.

VK2735 is expected to progress toward a triple-agonist formulation.

It is part of a broader trend of multi-agonist therapies in metabolic disease.

Viking Therapeutics aims to differentiate VK2735 from existing treatments like Tirzepatide and Retatrutide.

Clinical data is still emerging, with efficacy and safety profiles under investigation.

 Where this fits in the pipeline

VK2735 is currently in early clinical development, with publicly available data suggesting ongoing Phase 1 trials. While specific trial outcomes remain undisclosed, Viking Therapeutics has indicated plans to explore the compound's potential as a triple agonist, which would encompass additional pathways beyond GLP-1 and GIP. This positions VK2735 within a competitive field that includes other multi-agonists such as Tirzepatide and Retatrutide, as well as emerging candidates like HM15275 from Hanmi and Survodutide from Boehringer Ingelheim. The evolving landscape will likely influence VK2735's positioning and development trajectory.

 What it could mean for patients

If VK2735 demonstrates favorable outcomes in clinical trials, it could provide patients with a more effective option for weight management and metabolic control. The potential for a triple-agonist approach may enhance therapeutic effects, offering improved weight loss and metabolic benefits compared to existing single or dual agonists. However, patient outcomes will depend on the compound's safety profile and tolerability, which are crucial factors in the acceptance and integration of new therapies into clinical practice.

 Open questions and what we don't yet know

Several uncertainties remain regarding VK2735's development. Key questions include its long-term safety and efficacy compared to established therapies, as well as the specific mechanisms that will be targeted in future triple-agonist formulations. Additionally, the regulatory pathway for VK2735 is not fully defined, and potential engineering hurdles may arise as the compound advances toward more complex formulations. Ongoing trials will provide critical insights into these areas, but until then, the full potential of VK2735 remains speculative.

 Bottom line

VK2735 is a promising dual GLP-1/GIP agonist in the early stages of clinical development, with aspirations to evolve into a triple-agonist therapy. Its success will depend on forthcoming clinical data and its ability to navigate a competitive marketplace.

 This article is research-only educational content and is not medical advice. None of the drugs discussed are approved as quad-agonists or penta-agonists at the time of writing.

## Sources